Samsung Biologics Secures Record-Breaking $2 Trillion CMO Deal with European Pharma
Kim Jisun
stockmk2020@alphabiz.co.kr | 2025-01-15 06:44:58
Samsung Biologics. (Photo: Samsung Biologics)
[Alpha Biz= Kim Jisun] Samsung Biologics Secures Record $2 Trillion Biopharmaceutical CMO Deal
Samsung Biologics announced on Tuesday that it has signed its largest-ever contract manufacturing organization (CMO) agreement, worth 2.0747 trillion won ($1.41 billion), with a European pharmaceutical company.
The contract accounts for 40% of the company’s total 2023 orders, valued at 5.4035 trillion won. The agreement will last until December 31, 2030, though the product details remain undisclosed due to confidentiality agreements.
This record-breaking deal comes just three months after Samsung Biologics set a previous record with a 1.7028 trillion won agreement with an Asia-based pharmaceutical firm in October 2023.
[ⓒ AlphaBIZ. 무단전재-재배포 금지]
많이 본 기사
- 1KOSPI Rally Drives Margin Debt to Record High, Raising Volatility Concerns
- 2Hanwha Solutions Beats Q1 Estimates, Brokerages Turn Bullish on U.S. Solar Growth
- 3SK Group to Buy Back SK ecoplant Shares from FIs for KRW 1.05 Trillion Amid IPO Delays
- 4Hanwha Vision Profit Slumps in Q1 on Semiconductor Equipment Gap
- 5LG Energy Solution Seals KRW 25 Trillion Battery Alliance with Mercedes-Benz Across LFP and Next-Gen 46-Series
- 6BTS Holds Top 3 on Billboard Global Charts for Fifth Straight Week with ‘SWIM’